StockWatch
·

JENBURKT PHARMACEUTICALS LTD.

BSE: 524731

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
50.57
+36.6%+6.2%
Expenditure
36.23
+19.7%+8.8%
Net Profit
10.21
+73.5%+0.5%
OPM %
26.94%
+9.97pp-1.82pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.0014.1628.3242.4856.64Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

Jenburkt Q2 FY27: PAT flat YoY at ₹10.2 Cr as margins compress despite 6% revenue growth

pharmaceuticals · margin compression · capex capitalization

ResultsQ2 FY2703 Nov 20263 minPharma & Healthcare

Jenburkt Q1 FY27: PAT falls 24% YoY as staff costs surge, margins compress

pharmaceuticals · margin compression · employee costs

ResultsQ1 FY2706 Aug 20263 minPharma & Healthcare
Latest
Quarterly Result3 Nov, 6:00 pm

Jenburkt Q2 FY27: PAT flat YoY at ₹10.2 Cr as margins compress despite 6% revenue growth

Jenburkt's standalone Q2 FY27 revenue rose 6.1% YoY to ₹48.32 Cr, but PAT was effectively flat YoY at ₹10.21 Cr (+0.5%), with EPS at ₹23.13 against ₹23.03 a year ago. Both margins compressed on a YoY basis — OPM to 26.93% from 28.76%, NPM to 20.19% from 21.34% — so the topline gain did not flow through to the bottom line. QoQ the print looks strong (revenue +36.1%, PAT +73.5%), but that is a rebound off an unusually soft Q1 FY27 (₹35.51 Cr revenue, 16.97% OPM) rather than a new growth trend, and should be read that way rather than as momentum. The YoY margin squeeze traces to employee costs up 6.8% (₹14.87 Cr vs ₹13.93 Cr), roughly tracking revenue, but depreciation (+7.4% YoY to ₹0.799 Cr) and finance costs (+20.8% YoY to ₹0.130 Cr) rose faster. Both are tied to a large capex capitalization this quarter: PP&E jumped to ₹65.64 Cr from ₹11.30 Cr at FY26-end as capital work-in-progress fell from ₹46.12 Cr to ₹3.28 Cr, implying a new facility or line went live in the period — a cost step-up that will now run through the P&L each quarter. Separately, the effective tax rate normalized to 28.8% this quarter from Q1 FY27's unusually low 13.1% (a deferred-tax credit then), which is why PAT's QoQ gain (+73.5%) trailed PBT's QoQ gain (+111.8%). There is no prior management guidance or concall commentary on record for this company, and no analyst/street estimates could be located for this quarter — Jenburkt is an uncovered micro-cap, so vsStreet and vsGuidance are both unknown rather than a miss. No press release or management commentary beyond the bare regulatory filing was available to cross-check against. Among the quarter's other developments, Counter Cyclical Investment crossed a 5% stake (Oct 12) and the stock received NSE trading permission (Sep 22) — both ownership/liquidity items, not P&L drivers — while the Sr VP-International Business resigned (Sep 18) during the quarter, a development worth watching given the company's export exposure, though the filing discloses no segment or geography breakup to size any impact. Going into Q3 FY27, the key question is whether revenue growth from the newly capitalized capacity is enough to absorb the higher depreciation and finance-cost run-rate, or whether margins stay compressed at the Q2 level.

3 Nov 2026, 06:00 pm

Corporate Events

Board MeetingJENBURPH
2026
3Nov

Board Meeting

The Board of Directors meeting is scheduled to consider and …

BSE Filing ↗
Board MeetingJENBURPH
2026
4Sep

Board Meeting

The 41st Annual General Meeting (AGM) will be held on Friday…

BSE Filing ↗
Board MeetingJENBURPH
2026
6Aug

Board Meeting

The meeting of the Board of Directors is scheduled to consid…

BSE Filing ↗
Board MeetingJENBURPH
2025
28Jan

Board Meeting

Approval of standalone unaudited financial results for the q…

BSE Filing ↗
Board MeetingJENBURPH
2024
5Nov

Board Meeting

Consider and approve Standalone unaudited financial results …

BSE Filing ↗
Board MeetingJENBURPH
2024
6Feb

Board Meeting

consider and approve the Standalone unaudited financial resu…

BSE Filing ↗
Board MeetingJENBURPH
2023
7Nov

Board Meeting

consider and approve unaudited financial results for the qua…

BSE Filing ↗